Golden imperial chrysanthemum sourced 3 beta, 19 alpha-dihydroxy oleanole-12-ene-3-O-palmitate and application thereof

By isolating and identifying the natural pentacyclic triterpenoid palmitate 3β,19α-dihydroxyolean-12-ene-3-O-palmitate from Chrysanthemum indicum, the problem of this compound not being studied in the prior art was solved, achieving highly efficient inhibition of α-glucosidase and cellular glucose consumption, demonstrating significant hypoglycemic potential.

CN118994293APending Publication Date: 2024-11-22JIANGSU YIAN FLOWER CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411083842.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There is a lack of reports on 3β,19α-dihydroxyoleanolic-12-ene-3-O-palmitate in Chrysanthemum morifolium, especially regarding its hypoglycemic activity and applications.

Method used

The natural pentacyclic triterpenoid palmitate 3β,19α-dihydroxyolean-12-ene-3-O-palmitate was isolated and identified from Chrysanthemum indicum. Its structure was verified by a series of spectra, and it was purified by a multi-step extraction method. It was found that it has α-glucosidase inhibitory activity and cellular glucose consumption-promoting activity.

Benefits of technology

This compound exhibits significant α-glucosidase inhibitory activity, with an IC50 of 13.65 μM, which is 18 times higher than that of clinically used acarbose. It also has glucose consumption-promoting activity at a concentration of 50 μM comparable to that of 500 μM metformin, demonstrating a good hypoglycemic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994293A_ABST
    Figure CN118994293A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of natural medicines, and discloses a novel natural pentacyclic triterpene palmitate derived from golden chrysanthemum. According to the invention, a new pentacyclic triterpenoid is separated, extracted and structurally identified from golden chrysanthemum for the first time, the Chinese name of the new pentacyclic triterpenoid is called 3 beta, 19 alpha-dihydroxy olean-12-ene-3-O-palmitate, the English name of the new pentacyclic triterpenoid is 3 beta, 19 alpha-Dihydroxylan-12-en-3-O-palmitate, the structure of the new pentacyclic triterpenoid is # imgabs 0 #, and the content of the new pentacyclic triterpenoid is 0.0147%. The compound is separated, extracted and structurally identified from golden chrysanthemum for the first time, and the activity of the compound in the aspect of reducing blood sugar is found for the first time. Therefore, the compound and the golden chrysanthemum extract containing the compound can be applied to preparation of food and medicine products and raw materials for treating hyperglycemia related diseases such as diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of natural medicines, and in particular to a natural 3β,19α-dihydroxyolean-12-ene-3-O-palmitate derived from golden chrysanthemum and its application in preparing therapeutic hypoglycemic food and / or medicine. Background Art

[0002] Natural resources and natural products are the main sources of new drug discovery, as well as functional foods and food additives. Chrysanthemum, as a tea, has a good preventive effect on hypertension, cardiovascular diseases and cancer. It can also be used as medicine, with antioxidant, antibacterial, anti-tumor, anti-inflammatory, antiviral and other pharmacological effects. Golden chrysanthemum belongs to the genus Chrysanthemum of the Asteraceae family and has extremely high ornamental, edible and medicinal value. At present, there are many reports on the active substances of common varieties of chrysanthemums such as Hangbai Chrysanthemum, but the relevant research on the active substances in Golden chrysanthemum is very limited.

[0003] Chamomile contains abundant volatile oils, among which terpenes are the main active medicinal ingredients. The volatile oils contain eucalyptol, limonene, α-pinene, terpineol and other monoterpenes, matricaria, β-caryophyllene, α-farnesene and bisabolol and their oxides. Sesquiterpene derivatives are particularly abundant in inflorescences. Bisabolol is an important industrial additive. It is a colorless or light yellow low-toxic sesquiterpene with a unique sweet taste and aroma. It is insoluble in water, but soluble in ethanol, fat and oil. Ukiya et al. isolated 6 known triterpene fatty acid esters from the soluble lipids and non-saponifiable lipid fractions of the n-hexane extract of chrysanthemum.

[0004] α-glucosidase plays a very important role in the absorption of food. α-glucosidase can hydrolyze starch into glucose. Inhibiting this enzyme can slow down the rate at which starch breaks down into glucose, reduce and slow down the absorption of glucose in the small intestine, and thus play a role in lowering blood sugar. Acarbose, voglibose, and miglitol used clinically all belong to this type of drug. Therefore, α-glucosidase has a more obvious effect on lowering postprandial blood sugar, and it does not stimulate the secretion of insulin. Hypoglycemia usually does not occur when used alone, and it can help reduce blood sugar fluctuations. However, this type of drug has adverse reactions, which are mainly manifested in the gastrointestinal tract. For example, patients may experience gastrointestinal bloating, abdominal pain or discomfort, and may also experience nausea, vomiting, diarrhea and other related symptoms. Therefore, it is of great significance and application prospects to discover new α-glucosidase inhibitors with low toxic side effects from food.

[0005] So far, there are few reports on pentacyclic triterpenoids in Chrysanthemum morifolium. There is no report on 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, let alone the hypoglycemic activity of 3β,19α-dihydroxyolean-12-ene-3-O-palmitate.

[0006] Through searching, the following 1 public document related to the patent application of the present invention was found:

[0007] Journal article: Ukiya M, Akihisa T, Yasukawa K, et al. Constituents of composite plants. 2. Triterpene diols, triols, and their 3-O-fatty acid esters from edible chrysanthemum flower extract and their anti-inflammatory effects [J]. Journal of Agricultural and Food Chemistry, 2001, 49 (7): 3187-3197. Triterpenes and their fatty acid esters were isolated and extracted from a n-hexane extract of chrysanthemum, but the triterpene structure was different from the triterpene structure of the present invention.

[0008] In the prior art, there is no report on 3β,19α-dihydroxyolean-12-ene-3-O-palmitate. This natural product is a new compound, which was isolated and purified from Chrysanthemum morifolium for the first time. Its structure was verified by a series of spectra, and there is no report on any pharmacological activity. Summary of the invention

[0009] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a natural pentacyclic triterpene palmitate derived from golden chrysanthemum, an extraction and identification method, and an application in the preparation of therapeutic hypoglycemic foods and drugs.

[0010] The technical solution adopted by the present invention to solve its technical problem is:

[0011] A natural pentacyclic triterpene palmitate derived from golden chrysanthemum, the Chinese name of the pentacyclic triterpene palmitate is: 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, the English name is: 3β,19α-Dihydroxyolean-12-en-3-O-palmitate, and the structural formula is:

[0012]

[0013] Furthermore, the spectral attribution data of the pentacyclic triterpene palmitate are as follows: HR-ESI-MS (m / z703.5987[M+Na] + ,calcd.for C 46 H 80 O3Na + ,703.6000); 1 H NMR (400MHz, CDCl3) δ5.24(dt,J=3.3Hz,1H),4.49(t,J=8.6Hz,1H),4.19(dd,J=11.3,4.8Hz,1H),2.29(t,J=7.4Hz ,2H),2.15(dd,J=13.6,4.4Hz,1H),1.88-1.80(m,2H),1.71-1.68(m,1H),1.66-1.61(m,5H),1.58-1.50(m,4H),1.4 2-1.39(m,2H),1.32-1.28(m,5H),1.25(s,22H),1.21(s,3H),1.14(s,2H),1.08-1.05(m,1H),1.04-1.02(m,1H),0. 98(s,3H),0.96(s,3H),0.90(s,3H),0.89(s,3H),0.87(s,3H),0.87(s,3H),0.87(s,3H),0.82(s,1H),0.79(s,3H). 13C NMR (150MHz, CDCl3) δ46.6(C-1),23.7(C-2),80.6(C-3),37.9(C-4),55.4(C- 5),18.4(C-6),35.7(C-7),40.0(C-8),46.9(C-9),36.9(C-10),23.7(C-11),1 22.3(C-12),143.7(C-13),43.9(C-14),29.3(C-15),29.4(C-16),37.5(C-17 ),49.2(C-18),66.1(C-19),31.0(C-20),32.7(C-21),38.4(C-22),27.2(C-23 ),24.1(C-24),15.7(C-25),16.9(C-26),21.6(C-27),17.0(C-28),33.4(C-2 9),28.2(C-30),173.9(C-1′),35.0(C-2′),25.3(C-3′),29.5(C-4′),29.6(C- 5′),29.7(C-6′),29.8(C-7′),29.8(C-8′),29.8(C-9′),29.8(C-10′),29.8(C -11′), 30.7(C-12′), 32.1(C-13′), 34.3(C-14′), 22.8(C-15′), 14.3(C-16′).

[0014] Furthermore, the pentacyclic triterpene palmitate has α-glucosidase inhibitory activity and glucose consumption promoting activity at the cellular level; the pentacyclic triterpene palmitate has α-glucosidase inhibitory activity, and its IC 50 =13.65 μM, which is lower than the clinically used α-glucosidase inhibitor acarbose (IC 50 =250.14 μM) was 18 times higher; in addition, at a concentration of 50 μM, the compound had significant glucose consumption promoting activity, and 50 μM of pentacyclic triterpene palmitate was even comparable to the activity of 500 μM of metformin.

[0015] The above-mentioned method for separation, extraction and structural identification of natural pentacyclic triterpene palmitate comprises the following steps:

[0016] (1) Preparation method of golden chrysanthemum ethanol extract

[0017] First, the dried golden chrysanthemum flowers were crushed to obtain golden chrysanthemum powder, and the powder was placed in a round-bottom flask, and 95% ethanol was added at a solid-liquid ratio of 1:10. The extraction was performed under reflux at 95°C for 2 times, each time for 2 hours, and the 2 extracts were combined and concentrated under reduced pressure to obtain an ethanol extract, with a total extraction rate of 40.27%;

[0018] (2) Method for refining golden chrysanthemum ethanol extract

[0019] S1: Petroleum ether fractionation method of extract

[0020] Ultrasonic dispersion of the alcohol extract in water, with a solid-liquid ratio of g:mL of 1:10, extraction of the dispersed aqueous solution with petroleum ether for 3 times, with a petroleum ether:alcohol extract ratio of mL:g of 300:20, combining the petroleum ether layers and concentrating under reduced pressure; repeating the above operation 50 times to obtain a PE layer extract;

[0021] S2: Macroporous resin enrichment of extracts

[0022] Add ethanol EtOH to the PE layer extract and ultrasonicate until dissolved; wet sample loading, separation with AB-8 macroporous resin, elution gradient EtOH / H2O (0%, 20%, 40%, 60%, 80%, 100%, v / v, volume ratio), elution volume of each gradient for every 20g PE layer extract is 2.4L, and 6 components, namely PE0-PE100, are obtained after elution; repeat the above operation 7 times to obtain components PE0, PE20, PE40, PE60, PE80 and PE100;

[0023] S3: Silica gel column separation method for extracts

[0024] Component PE100 has low polarity and good separation on TLC, so silica gel column chromatography is used to roughly segment component PE100; component PE100 is separated by silica gel column, and the elution gradient is PE: acetone AC = 500: 1 ~ 30: 1 (v / v, volume ratio), DCM: MeOH = 100: 1 ~ 0: 1 (v / v, volume ratio), and 8 components, namely PE100-1, PE100-2, PE100-3, PE100-4, PE100-5, PE100-6, PE100-7, PE100-8) are obtained;

[0025] S4: Purification method of target compound in extract

[0026] Component PE100-2 was separated by a silica gel column with an elution gradient of PE:AC = 400:1 to 200:1 (v / v, volume ratio) to obtain three components, namely PE100-2-1, PE100-2-2, and PE100-2-3; component PE100-2-3 was separated by a silica gel column with an elution gradient of PE:AC = 400:1 to 30:1 (v / v, volume ratio) to obtain six components, namely PE100-2-3-1, PE100-2-3-2, PE100-2-3-3, PE100-2-3-4, PE100-2-3-5, and PE100-2-3-6; component PE100-2-3-5 was separated by an ODS reverse phase column and eluted with MeOH to obtain 87.0 mg of the target compound, with a yield of 0.0147% calculated from the petals of Chrysanthemum morifolium.

[0027] A golden chrysanthemum extract containing the above-mentioned 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, wherein the content of the 3β,19α-dihydroxyolean-12-ene-3-O-palmitate in the extract is 0.001% to 90% (mass ratio), and the preparation steps of the golden chrysanthemum extract are as follows:

[0028] (1) Preparation method of golden chrysanthemum ethanol extract

[0029] First, the dried golden chrysanthemum flowers were crushed to obtain golden chrysanthemum powder, and the powder was placed in a round-bottom flask, and 95% ethanol was added at a solid-liquid ratio of 1:10. The extraction was performed under reflux at 95°C for 2 times, each time for 2 hours, and the 2 extracts were combined and concentrated under reduced pressure to obtain an ethanol extract, with a total extraction rate of 40.27%;

[0030] (2) Method for refining golden chrysanthemum ethanol extract

[0031] S1: Petroleum ether fractionation method of extract

[0032] Ultrasonic dispersion of the alcohol extract in water, with a solid-liquid ratio of g / mL of 1:10, extraction of the dispersed aqueous solution with petroleum ether for 3 times, with a petroleum ether: alcohol extract ratio of mL:g of 300:20, combining the petroleum ether layers and concentrating under reduced pressure; repeating the above operation 50 times to obtain a PE layer extract;

[0033] S2: Macroporous resin enrichment of extracts

[0034] Add ethanol EtOH to the PE layer extract and ultrasonicate until dissolved; wet sample loading, separation with AB-8 macroporous resin, elution gradient EtOH / H2O (0%, 20%, 40%, 60%, 80%, 100%, v / v, volume ratio), elution volume of each gradient for every 20g PE layer extract is 2.4L, and 6 components, namely PE0-PE100, are obtained after elution; repeat the above operation 7 times to obtain components PE0, PE20, PE40, PE60, PE80 and PE100;

[0035] S3: Silica gel column separation method for extracts

[0036] Component PE100 has low polarity and good separation on TLC, so silica gel column chromatography is used to roughly segment component PE100; component PE100 is separated by silica gel column, and the elution gradient is PE: acetone AC = 500: 1 ~ 30: 1 (v / v, volume ratio), DCM: MeOH = 100: 1 ~ 0: 1 (v / v, volume ratio), and 8 components, namely PE100-1, PE100-2, PE100-3, PE100-4, PE100-5, PE100-6, PE100-7, PE100-8) are obtained;

[0037] S4: Purification method of target compound in extract

[0038] The component PE100-2 was separated by a silica gel column with an elution gradient of PE:AC=400:1-200:1 (v / v, volume ratio), and three components were obtained, namely PE100-2-1, PE100-2-2, and PE100-2-3; the component PE100-2-3 was separated by a silica gel column with an elution gradient of PE:AC=400:1-30:1 (v / v, volume ratio), and six components were obtained, namely PE100-2-3-1, PE 100-2-3-2, PE100-2-3-3, PE100-2-3-4, PE100-2-3-5, PE100-2-3-6; component PE100-2-3-5 was separated by ODS reverse phase column and eluted with MeOH to obtain the target compound containing 0.001% to 90% (mass ratio), that is, the golden chrysanthemum extract containing 3β,19α-dihydroxyolean-12-ene-3-O-palmitate.

[0039] The use of the natural pentacyclic triterpene palmitate as described above as a marker for and / or in the preparation of a chrysanthemum extract for food or drug addition.

[0040] The use of the natural pentacyclic triterpene palmitate as described above in the preparation of medicines and / or functional foods for treating diabetes.

[0041] The use of the natural pentacyclic triterpene palmitate as described above in the preparation of drugs for treating hyperglycemia-related diseases.

[0042] Use of the golden chrysanthemum extract containing natural pentacyclic triterpene palmitate as described above in the preparation of blood sugar-lowering food and / or medicine.

[0043] The advantages and positive effects achieved by the present invention are:

[0044] 1. The present invention separates, extracts and identifies a new pentacyclic triterpene from Goldenrod for the first time, named 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, with a content of 0.0147%. The present invention separates, extracts and identifies the compound from Goldenrod for the first time, and finds for the first time that the compound has hypoglycemic activity. The compound can be used as a marker to prepare Goldenrod extract with hypoglycemic activity, which can be used for food and drug addition, or it can be used as a single ingredient in the preparation of food and drug for the treatment of hyperglycemia-related diseases such as diabetes.

[0045] 2. This invention is the first to evaluate the in vitro α-glucosidase inhibitory activity and glucose consumption promoting activity at the cellular level of the natural pentacyclic triterpene palmitate derived from golden chrysanthemum. The results showed that the compound has good α-glucosidase inhibitory activity, and the half inhibitory concentration (IC 50 ) was 13.65 μM, which was lower than the clinically used α-glucosidase inhibitor acarbose (IC 50 =250.14 μM) is 18 times higher. In addition, at a concentration of 50 μM, the compound has significant glucose consumption promoting activity, and even the activity of the compound at a concentration of 50 μM is equivalent to that of 500 μM metformin. Therefore, it is shown that the compound has good hypoglycemic activity.

[0046] 3. Golden chrysanthemum is a top-grade chrysanthemum with a history of hundreds of years of consumption. A new type of hypoglycemic ingredient was found from this plant, which has the advantage of low toxicity. Therefore, 3β,19α-dihydroxyolean-12-ene-3-O-palmitate and its extracts with a certain content can be used as functional foods and / or drugs for the treatment of hyperglycemia-related diseases, with the characteristics of low food-borne toxicity and side effects, and has huge market potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 is the hydrogen nuclear magnetic resonance spectrum of the compound of the present invention ( 1 H NMR) spectra;

[0048] Figure 2 is the carbon NMR spectrum of the compound of the present invention ( 13 C NMR) spectra;

[0049] Figure 3 DEPT 90 diagram of the compound of the present invention;

[0050] Figure 4 DEPT 135 diagram of the compound of the present invention;

[0051] Figure 5 The compounds of the present invention 1 H- 1 H COSY diagram;

[0052] Figure 6 is the HSQC diagram of the compound of the present invention;

[0053] Figure 7 is the HMBC diagram of the compound of the present invention;

[0054] Figure 8 is the NOESY diagram of the compound of the present invention;

[0055] Fig. 9 is a high-resolution mass spectrum of the compound of the present invention;

[0056] Fig.10 is the half inhibitory concentration (IC 50 ) curve graph;

[0057] Fig.11 The figure shows the glucose consumption promoting activity of the compounds of the present invention at the cellular level. DETAILED DESCRIPTION

[0058] The present invention will be further described below in conjunction with the embodiments. The following embodiments are descriptive rather than restrictive, and the protection scope of the present invention cannot be limited by the following embodiments.

[0059] The various experimental operations involved in the specific embodiments are all routine techniques in the art. For parts not specially annotated in this document, ordinary technicians in the art can implement them by referring to various commonly used reference books, scientific and technological literature or related instructions, manuals, etc. before the filing date of this invention.

[0060] A natural pentacyclic triterpene palmitate derived from golden chrysanthemum, the Chinese name of the pentacyclic triterpene palmitate is: 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, the English name is: 3β,19α-Dihydroxyolean-12-en-3-O-palmitate, and the structural formula is:

[0061]

[0062] Preferably, the spectrum attribution data of the pentacyclic triterpene palmitate is as follows: HR-ESI-MS (m / z 703.5987 [M+Na] + ,calcd.for C 46 H 80 O3Na + ,703.6000); 1 H NMR (400MHz, CDCl3) δ5.24(dt,J=3.3Hz,1H),4.49(t,J=8.6Hz,1H),4.19(dd,J=11.3,4.8Hz,1H),2.29(t,J=7.4Hz ,2H),2.15(dd,J=13.6,4.4Hz,1H),1.88-1.80(m,2H),1.71-1.68(m,1H),1.66-1.61(m,5H),1.58-1.50(m,4H),1.4 2-1.39(m,2H),1.32-1.28(m,5H),1.25(s,22H),1.21(s,3H),1.14(s,2H),1.08-1.05(m,1H),1.04-1.02(m,1H),0. 98(s,3H),0.96(s,3H),0.90(s,3H),0.89(s,3H),0.87(s,3H),0.87(s,3H),0.87(s,3H),0.82(s,1H),0.79(s,3H). 13C NMR (150MHz, CDCl3) δ46.6(C-1),23.7(C-2),80.6(C-3),37.9(C-4),55.4(C- 5),18.4(C-6),35.7(C-7),40.0(C-8),46.9(C-9),36.9(C-10),23.7(C-11),1 22.3(C-12),143.7(C-13),43.9(C-14),29.3(C-15),29.4(C-16),37.5(C-17 ),49.2(C-18),66.1(C-19),31.0(C-20),32.7(C-21),38.4(C-22),27.2(C-23 ),24.1(C-24),15.7(C-25),16.9(C-26),21.6(C-27),17.0(C-28),33.4(C-2 9),28.2(C-30),173.9(C-1′),35.0(C-2′),25.3(C-3′),29.5(C-4′),29.6(C- 5′),29.7(C-6′),29.8(C-7′),29.8(C-8′),29.8(C-9′),29.8(C-10′),29.8(C -11′), 30.7(C-12′), 32.1(C-13′), 34.3(C-14′), 22.8(C-15′), 14.3(C-16′).

[0063] Preferably, the pentacyclic triterpene palmitate has α-glucosidase inhibitory activity and glucose consumption promoting activity at the cellular level; the pentacyclic triterpene palmitate has α-glucosidase inhibitory activity, and its IC 50 =13.65 μM, which is lower than the clinically used α-glucosidase inhibitor acarbose (IC 50 =250.14 μM) was 18 times higher; in addition, at a concentration of 50 μM, the compound had significant glucose consumption promoting activity, and 50 μM of the pentacyclic triterpene palmitate was even comparable to the activity of 500 μM metformin.

[0064] The above-mentioned method for separation, extraction and structural identification of natural pentacyclic triterpene palmitate comprises the following steps:

[0065] (1) Preparation method of golden chrysanthemum ethanol extract

[0066] First, the dried golden chrysanthemum flowers were crushed to obtain golden chrysanthemum powder, and the powder was placed in a round-bottom flask, and 95% ethanol was added at a solid-liquid ratio of 1:10. The extraction was performed under reflux at 95°C for 2 times, each time for 2 hours, and the 2 extracts were combined and concentrated under reduced pressure to obtain an ethanol extract, with a total extraction rate of 40.27%;

[0067] (2) Method for refining golden chrysanthemum ethanol extract

[0068] S1: Petroleum ether fractionation method of extract

[0069] Ultrasonic dispersion of the alcohol extract in water, with a solid-liquid ratio of g:mL of 1:10, extraction of the dispersed aqueous solution with petroleum ether for 3 times, with a petroleum ether:alcohol extract ratio of mL:g of 300:20, combining the petroleum ether layers and concentrating under reduced pressure; repeating the above operation 50 times to obtain a PE layer extract;

[0070] S2: Macroporous resin enrichment of extracts

[0071] Add ethanol EtOH to the PE layer extract and ultrasonicate until dissolved; wet sample loading, separation with AB-8 macroporous resin, elution gradient EtOH / H2O (0%, 20%, 40%, 60%, 80%, 100%, v / v, volume ratio), elution volume of each gradient for every 20g PE layer extract is 2.4L, and 6 components, namely PE0-PE100, are obtained after elution; repeat the above operation 7 times to obtain components PE0, PE20, PE40, PE60, PE80 and PE100;

[0072] S3: Silica gel column separation method for extracts

[0073] Component PE100 has low polarity and good separation on TLC, so silica gel column chromatography is used to roughly segment component PE100; component PE100 is separated by silica gel column, and the elution gradient is PE: acetone AC = 500: 1 ~ 30: 1 (v / v, volume ratio), DCM: MeOH = 100: 1 ~ 0: 1 (v / v, volume ratio), and 8 components, namely PE100-1, PE100-2, PE100-3, PE100-4, PE100-5, PE100-6, PE100-7, PE100-8) are obtained;

[0074] S4: Purification method of target compound in extract

[0075] Component PE100-2 was separated by a silica gel column with an elution gradient of PE:AC = 400:1 to 200:1 (v / v, volume ratio) to obtain three components, namely PE100-2-1, PE100-2-2, and PE100-2-3; component PE100-2-3 was separated by a silica gel column with an elution gradient of PE:AC = 400:1 to 30:1 (v / v, volume ratio) to obtain six components, namely PE100-2-3-1, PE100-2-3-2, PE100-2-3-3, PE100-2-3-4, PE100-2-3-5, and PE100-2-3-6; component PE100-2-3-5 was separated by an ODS reverse phase column and eluted with MeOH to obtain 87.0 mg of the target compound, with a yield of 0.0147% calculated from the dry petals of Chrysanthemum morifolium.

[0076] A golden chrysanthemum extract containing the above-mentioned 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, wherein the content of the 3β,19α-dihydroxyolean-12-ene-3-O-palmitate in the extract is 0.001% to 90% (mass ratio), and the steps of the extraction and separation method of the golden chrysanthemum extract are as follows:

[0077] (1) Preparation method of golden chrysanthemum ethanol extract

[0078] First, the dried golden chrysanthemum flowers were crushed to obtain golden chrysanthemum powder, and the powder was placed in a round-bottom flask, and 95% ethanol was added at a solid-liquid ratio of 1:10. The extraction was performed under reflux at 95°C for 2 times, each time for 2 hours, and the 2 extracts were combined and concentrated under reduced pressure to obtain an ethanol extract, with a total extraction rate of 40.27%;

[0079] (2) Method for refining golden chrysanthemum ethanol extract

[0080] S1: Petroleum ether fractionation method of extract

[0081] Ultrasonic dispersion of the alcohol extract in water, with a solid-liquid ratio of g / mL of 1:10, extraction of the dispersed aqueous solution with petroleum ether for 3 times, with a petroleum ether: alcohol extract ratio of mL:g of 300:20, combining the petroleum ether layers and concentrating under reduced pressure; repeating the above operation 50 times to obtain a PE layer extract;

[0082] S2: Macroporous resin enrichment of extracts

[0083] Add ethanol EtOH to the PE layer extract and ultrasonicate until dissolved; wet sample loading, separation with AB-8 macroporous resin, elution gradient EtOH / H2O (0%, 20%, 40%, 60%, 80%, 100%, v / v, volume ratio), elution volume of each gradient for every 20g PE layer extract is 2.4L, and 6 components, namely PE0-PE100, are obtained after elution; repeat the above operation 7 times to obtain components PE0, PE20, PE40, PE60, PE80 and PE100;

[0084] S3: Silica gel column separation method for extracts

[0085] Component PE100 has low polarity and good separation on TLC, so silica gel column chromatography is used to roughly segment component PE100; component PE100 is separated by silica gel column, and the elution gradient is PE: acetone AC = 500: 1 ~ 30: 1 (v / v, volume ratio), DCM: MeOH = 100: 1 ~ 0: 1 (v / v, volume ratio), and 8 components, namely PE100-1, PE100-2, PE100-3, PE100-4, PE100-5, PE100-6, PE100-7, PE100-8) are obtained;

[0086] S4: Purification method of target compound in extract

[0087] The component PE100-2 was separated by a silica gel column with an elution gradient of PE:AC=400:1-200:1 (v / v, volume ratio), and three components were obtained, namely PE100-2-1, PE100-2-2, and PE100-2-3; the component PE100-2-3 was separated by a silica gel column with an elution gradient of PE:AC=400:1-30:1 (v / v, volume ratio), and six components were obtained, namely PE100-2-3-1, PE 100-2-3-2, PE100-2-3-3, PE100-2-3-4, PE100-2-3-5, PE100-2-3-6; component PE100-2-3-5 was separated by ODS reverse phase column and eluted with MeOH to obtain the target compound containing 0.001% to 90% (mass ratio), that is, the golden chrysanthemum extract containing 3β,19α-dihydroxyolean-12-ene-3-O-palmitate.

[0088] The use of the natural pentacyclic triterpene palmitate as described above as a marker for and / or in the preparation of a chrysanthemum extract for food or drug addition.

[0089] The use of the natural pentacyclic triterpene palmitate as described above in the preparation of medicines and / or functional foods for treating diabetes.

[0090] The use of the natural pentacyclic triterpene palmitate as described above in the preparation of drugs for treating hyperglycemia-related diseases.

[0091] Use of the golden chrysanthemum extract containing natural pentacyclic triterpene palmitate as described above in the preparation of blood sugar-lowering food and / or medicine.

[0092] Specifically, the relevant preparation and detection are as follows:

[0093] Example 1

[0094] Preparation of a golden chrysanthemum extract containing 3β,19α-dihydroxyolean-12-ene-3-O-palmitate

[0095] The steps of the extraction and separation method are as follows:

[0096] (1) Preparation method of golden chrysanthemum ethanol extract

[0097] First, the dried golden chrysanthemum flowers were crushed to obtain golden chrysanthemum powder, and the powder (50 g) was placed in a 1000 mL round-bottom flask. 95% ethanol (EtOH) (solid-liquid ratio 1:10) was added, and reflux extraction was performed at 95°C twice, each time for 2 h. The two extracts were combined and concentrated under reduced pressure to obtain an alcohol extract. The total extraction rate was 40.27%.

[0098] (2) Method for refining golden chrysanthemum ethanol extract

[0099] S1: Petroleum ether fractionation method of extract

[0100] The EtOH extract (20 g) was ultrasonically dispersed in water (solid-liquid ratio 1:10, g / mL), the dispersed aqueous solution was poured into a 1000 mL separatory funnel, extracted with petroleum ether (300 mL) three times, the petroleum ether (PE) layers were combined, and concentrated under reduced pressure. The above operation was repeated 50 times to obtain a total of 290.3 g of PE layer extract.

[0101] S2: Macroporous resin enrichment of extracts

[0102] Put the PE layer extract (20g) into a conical flask, add EtOH and ultrasonicate until dissolved. Wet sample loading, separate with AB-8 macroporous resin, elution gradient is EtOH / H2O (0%, 20%, 40%, 60%, 80%, 100%, v / v, volume percentage), the elution volume of each gradient is 2.4L, and 6 components (PE0~PE100) are obtained at the end of elution. Repeat the above operation 7 times, and the weights of the components obtained are PE0 (13.0g), PE20 (5.0g), PE40 (14.0g), PE60 (16.0g), PE80 (8.0g) and PE100 (61.0g).

[0103] S3: Silica gel column separation method for extracts

[0104] Component PE100 has low polarity and good separation on TLC, so silica gel column chromatography is used to roughly segment component PE100. Component PE100 (30 g) is separated by silica gel column, and the elution gradient is PE: acetone (AC) = 500: 1 ~ 30: 1 (v / v, volume ratio), DCM: MeOH = 100: 1 ~ 0: 1 (v / v, volume ratio), and 8 components (PE100-1 ~ PE100-8) are obtained. The weight of each component is PE100-1 (4.0 g), PE100-2 (2.0 g), PE100-3 (4.0 g), PE100-4 (5.0 g), PE100-5 (2.0 g), PE100-6 (4.0 g), PE100-7 (4.0 g) and PE100-8 (4.0 g).

[0105] S4: Purification method of target compound in extract

[0106] Component PE100-2 (2.0 g) was separated by a silica gel column with an elution gradient of PE:AC=400:1 to 200:1 (volume ratio), and three components (PE100-2-1 to PE100-2-3) were obtained. Component PE100-2-3 was separated by a silica gel column with an elution gradient of PE:AC=400:1 to 30:1 (volume ratio), and six components (PE100-2-3-1 to PE100-2-3-6) were obtained. Component PE100-2-3-5 was separated by an ODS reverse phase column, and MeOH was used for elution to obtain a golden chrysanthemum extract containing 0.001% to 90% (mass ratio) of 3β,19α-dihydroxyolean-12-ene-3-O-palmitate.

[0107] Example 2

[0108] Structural Identification of 3β,19α-Dihydroxyolean-3-O-palmitate

[0109] (1) Structural identification conditions and methods

[0110] The present invention uses nuclear magnetic resonance spectroscopy ( 1 H-NMR, 13 C-NMR, DEPT, HMQC, 1 H- 1H COSY, NOESY and HMBC) and mass spectrometry (LC-MS and LC-HRMS) were used to characterize and analyze the structures of the above compounds. Among them, DEPT spectrum (Distortionless Enhancement by Polarization Transfer), called distortionless polarization transfer technology, is mainly used to distinguish primary carbon, secondary carbon, tertiary carbon and quaternary carbon in the carbon spectrum. HSQC (Heteronuclear Single Quantum Coherence) mainly provides directly connected carbon-hydrogen relationship information; HMBC (Heteronuclear Multiple Bond Correlation) provides more complex multi-bond carbon-hydrogen relationship information, especially the coupling information of protons and carbons of separated bonds (usually 2 to 3 bonds). 1 H- 1 H COSY is a hydrogen-hydrogen chemical shift correlation spectrum. NOESY (nuclear overhauser effect spectroscopy) gives spatially correlated hydrogen signals.

[0111] NMR spectroscopic conditions: Bruker AV-400 NMR spectrometer, δ: chemical shift (unit: ppm), J: coupling constant (unit: Hz). High-resolution mass spectrometric conditions: HPLC conditions: flow rate 0.2 mL / min, injection volume: 1 μL, column oven 25°C. Mobile phase A is water, and phase B is methanol (HPLC grade). (Gradient elution: 0-6 min, 100% B). Mass spectrometric conditions: In the range of m / z 50-1700, mass spectra were simultaneously obtained by electrospray ionization (ESI) at low and high fragmentation voltages (-3.5 KV and 4.5 KV).

[0112] (2) Structural inference method of 3β,19α-dihydroxyolean-12-ene-3-O-palmitate

[0113] The compound is a colorless oil. The color of sulfuric acid ethanol in thin layer chromatography is red, and it may be a terpene structure. According to its high resolution mass spectrometry (HR-ESI-MS) data (see attached Fig. 9 ) to determine its molecular formula is C 46 H 80 O3. Compounds 1 HNMR (see attached Figure 1 ), 13 C-NMR (see attached Figure 2 )、DEPT(see attached Figure 3 and 4 )and 1 H- 1 H COSY (see attached Figure 5) The spectrum data showed that the compound may be an oleanane skeleton. 1 In HNMR, δ H There is a characteristic peak at 5.24 (dt, J = 3.3 Hz, 1H), indicating an olefin proton. H There are two doublets at 4.19 (J = 11.3, 4.8 Hz, 1H) and 4.49 (J = 8.6 Hz, 1H), a triplet at 2.29 (J = 7.4 Hz, 2H), and 26 proton overlaps between 1.2 and 1.4, indicating the presence of two hydroxylated methines and a palmitate fragment. HSQC (see Appendix Figure 6 ) and DEPT spectra showed δ H 5.24 peak corresponds to δ C 122.3 (olefin methine), δ H 2.15 corresponds to δ C 49.2 (methyl). HMBC (see attached Figure 7 ) spectrum shows that H-18(δ H 2.15) and C-12(δ c 122.3) and C-13 (δ c 143.7) is related, C-19 (δ c 66.1) and H-12(δ H 5.24) and C-18 (δ c 49.2) is correlated, and it is inferred that the hydroxyl group (δ H 4.19) is located at C-19. NOESY of H-18 and H-12 (see Appendix Figure 8 ) correlations showed that oleanane was a trans-D / E ring. There was no NOESY correlation between H-18 and H-19, indicating that the 19-OH group was in an α orientation. In addition, the peak splitting of H-19 and the same coupling constants between H-18 and H-19 confirmed the α-OH group on C-19. Therefore, the structure of the compound was inferred to be 3β,19α-dihydroxyolean-12-ene-3-O-palmitate.

[0114] The specific spectrum is as follows: HR-ESI-MS (m / z 703.5987 [M+Na] + ,calcd.for C 46 H 80 O3Na + ,703.6000); 11H NMR (400 MHz, CDCl3) δ 5.24 (dt, J = 3.3 Hz, 1H), 4.49 (t, J = 8.6 Hz, 1H), 4.19 (dd, J = 11.3, 4.8 Hz, 1H), 2.29 (t, J = 7.4 Hz, 2H), 2.15 (dd, J = 13.6, 4.4 Hz, 1H), 1.88 - 1.80 (m, 2H), 1.71 - 1.68 (m, 1H), 1.66 - 1.61 (m, 5H), 1.58 - 1.50 (m, 4H), 1.42 - 1.39 (m, 2H), 1.32 - 1.28 (m, 5H), 1.25 (s, 22H), 1.21 (s, 3H), 1.14 (s, 2H), 1.08 - 1.05 (m, 1H), 1.04 - 1.02 (m, 1H), 0.98 (s, 3H), 0.96 (s, 3H), 0.90 (s, 3H), 0.89 (s, 3H), 0.87 (s, 3H), 0.87 (s, 3H), 0.87 (s, 3H), 0.82 (s, 1H), 0.79 (s, 3H). 13 13C NMR (150 MHz, CDCl3) δ 46.6 (C-1), 23.7 (C-2), 80.6 (C-3), 37.9 (C-4), 55.4 (C-5), 18.4 (C-6), 35.7 (C-7), 40.0 (C-8), 46.9 (C-9), 36.9 (C-10), 23.7 (C-11), 122.3 (C-12), 143.7 (C-13), 43.9 (C-14), 29.3 (C-15), 29.4 (C-16), 37.5 (C-17), 49.2 (C-18), 66.1 (C-19), 31.0 (C-20), 32.7 (C-21), 38.4 (C-22), 27.2 (C-23), 24.1 (C-24), 15.7 (C-25), 16.9 (C-26), 21.6 (C-27), 17.0 (C-28), 33.4 (C-29), 28.2 (C-30), 173.9 (C-1′), 35.0 (C-2′), 25.3 (C-3′), 29.5 (C-4′), 29.6 (C-5′), 29.7 (C-6′), 29.8 (C-7′), 29.8 (C-8′), 29.8 (C-9′), 29.8 (C-10′), 29.8 (C-11′), 30.7 (C-12′), 32.1 (C-13′), 34.3 (C-14′), 22.8 (C-15′), 14.3 (C-16′).

[0115] Example 3

[0116] Evaluation of α-glucosidase inhibitory activity of 3β,19α-dihydroxyolean-12-ene-3-O-palmitate

[0117] (1) Evaluation method of α-glucosidase inhibitory activity

[0118] (i) Preparation of 50 mM phosphate buffer (PB)

[0119] Accurately weigh 13.68g of potassium dihydrogen phosphate and 22.68g of potassium dihydrogen phosphate, add to a beaker, dissolve in water, transfer to a 500mL volumetric flask to make up to volume, and prepare a 0.4M buffer solution. Take 62.5mL of buffer solution and place it in a 500mL volumetric flask, make up to volume, transfer to a screw-cap bottle, and adjust the pH to 6.8 with phosphoric acid.

[0120] (ii) Preparation of α-glucosidase solution

[0121] PB (992 μL) was added to 5 U / mL α-glycosidase solution (8 μL) to dilute to 0.04 U / mL α-glycosidase solution.

[0122] (iii) Preparation of 4-nitrophenol-α-D-pyranoglucoside (p-NPG) test solution

[0123] PB was added with 10 mM p-NPG to dilute to 0.5 mM p-NPG test solution.

[0124] (iv) Determination of α-glucosidase inhibitory activity

[0125] The following reagents were added to a 96-well ELISA plate: PB (170 μL) was added to the blank group (OD1); PB (140 μL), DMSO (10 μL) and 0.04 U / mL α-glycosidase solution (20 μL) were added to the control group (OD2); PB (160 μL) was added to the compound blank group (OD3), and the compound to be tested was added; PB (140 μL) and 0.04 U / mL α-glycosidase solution (20 μL) were added to the compound test group (OD4), and the compound to be tested was added. After incubation at 37°C for 5 minutes, the substrate (30 μL) was added and incubated for 30 minutes. The absorbance value (OD) was measured at 405 nm using an ELISA reader, and the calculation formula is as follows:

[0126]

[0127] Table 1 α-glucosidase inhibitory activity of compounds

[0128] Compound Name 50μM inhibition rate (%) <![CDATA[IC 50 (μM)]]> 3β,19α-Dihydroxyolean-12-ene-3-O-palmitate 90.00±3.96 13.65 <![CDATA[Acarbose b > 31.87±0.28 250.14

[0129] Note: a All results for α-glucosidase are the means ± SD of three experiments;b Acarbose was used as a positive control.

[0130] As shown in Table 1, the compounds of the present invention have good α-glucosidase inhibitory activity at a concentration of 50 μM, and the half inhibition concentration (IC 50 ) The test results show that the IC 50 =13.65μM (see Fig.10 ), which is 18 times higher than the clinically used α-glucosidase inhibitor acarbose, indicating that the compound has good α-glucosidase inhibitory activity.

[0131] Example 4

[0132] Study on the hypoglycemic activity of 3β,19α-dihydroxyolean-12-ene-3-O-palmitate at the cellular level

[0133] The cellular glucose consumption experiment was used to further evaluate the amount of glucose consumption promoted by the compounds at different concentrations, thereby indirectly indicating the hypoglycemic activity. Metformin was used as a positive control, and the specific method was as follows:

[0134] HepG2 cells in the logarithmic growth phase were routinely digested and cultured in DMEM (dulbecco's modified eagle medium) low-glucose medium. The inoculation cell density was 5×10 4 / mL in a 96-well culture plate, 100μL per well, placed in an incubator and cultured overnight. After the cells adhered, the supernatant was discarded, washed once with 1×PBS, starved with serum-free DMEM high-glucose medium for 24h, washed once with 1×PBS, and cultured with DMEM high-glucose medium. A drug control group (culture medium + test substance + cells), a negative control group (culture medium + dimethyl sulfoxide solvent + cells) and a blank control group (culture medium + test substance) + a positive control group (culture medium + metformin + cells) were set up. Three replicate wells were set up for each concentration, and 0.5μL of compounds with concentrations of 0.5μM, 5μM and 50μM, or an equal volume of dimethyl sulfoxide solvent (negative control group), or an equal volume of 500μM metformin (positive control group) was added to each well. The cells were placed in a carbon dioxide incubator and continued to be cultured. After 24h, the relative glucose consumption was detected using a glucose determination kit. The results are the average of three independent experiments. The results are shown in the attached Fig.11 .

[0135] From the attached Fig.11 It can be seen that at the three tested concentrations, the compound has significant glucose consumption promoting activity, and 50 μM of the compound is even comparable to 500 μM of metformin. Therefore, the compound also has good hypoglycemic activity at the cellular level.

[0136] In summary, the present invention is the first to separate, extract and structurally identify a new natural compound from Golden Chrysanthemum, which is 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, and the compound is evaluated for its in vitro hypoglycemic activity. The results show that the compound can inhibit the activity of α-glucosidase in vitro, and its activity (IC 50 =13.65 μM) than the clinically used α-glucosidase inhibitor acarbose (IC 50 =250.14 μM) is 18 times higher; in addition, the compound can also promote cellular glucose consumption, and the activity of the compound at a concentration of 50 μM is even equivalent to that of 500 μM metformin. This shows that the natural pentacyclic triterpenoid compounds derived from golden chrysanthemum have good blood sugar-lowering effect.

[0137] 3β,19α-dihydroxyolean-12-ene-3-O-palmitate is a new compound, which is discovered for the first time. Its application in lowering blood sugar is also discovered for the first time. It can be used as a marker for extracts of golden chrysanthemum or other downstream products to prepare golden chrysanthemum food or medicine with hypoglycemic activity. In addition, the compound is derived from food and has the advantage of low toxicity and side effects compared to drugs. The compound also has certain development potential and application prospects in the field of new drug research and development.

[0138] Although the embodiments of the present invention are disclosed for illustrative purposes, those skilled in the art will appreciate that various substitutions, changes and modifications are possible without departing from the spirit and scope of the present invention and the appended claims. Therefore, the scope of the present invention is not limited to the contents disclosed in the embodiments.

Claims

1. A natural pentacyclic triterpene palmitate derived from Chrysanthemum cyrtonema, characterized in that: The pentacyclic triterpene palmitate is named in Chinese as 3β,19α-dihydroxyolean-12-ene-3-O-palmitate, and in English as 3β,19α-Dihydroxyolean-12-en-3-O-palmitate, with the structural formula as follows:

2. The natural pentacyclic triterpene palmitate according to claim 1, characterized in that: The spectral attribution data of the pentacyclic triterpene palmitate are as follows: HR-ESI-MS (m / z 703.5987 [M+Na] + ,calcd.for C 46 H 80 O3Na + ,703.6000); 1 H NMR (400MHz, CDCl3) δ5.24(dt,J=3.3Hz,1H),4.49(t,J=8.6Hz,1H),4.19(dd,J=11.3,4.8Hz,1H),2.29(t,J=7.4Hz ,2H),2.15(dd,J=13.6,4.4Hz,1H),1.88-1.80(m,2H),1.71-1.68(m,1H),1.66-1.61(m,5H),1.58-1.50(m,4H),1.4 2-1.39(m,2H),1.32-1.28(m,5H),1.25(s,22H),1.21(s,3H),1.14(s,2H),1.08-1.05(m,1H),1.04-1.02(m,1H),0. 98(s,3H),0.96(s,3H),0.90(s,3H),0.89(s,3H),0.87(s,3H),0.87(s,3H),0.87(s,3H),0.82(s,1H),0.79(s,3H). 13 C NMR(150MHz,CDCl3)δ46.6(C-1),23.7(C-2),80.6(C-3),37.9(C-4),55.4(C-5),18.4(C-6),35.7(C-7),40.0(C-8),46.9(C-9),36.9(C-10),23.7(C-11),122.3(C-12),143.7(C-13),43.9(C-14),29.3(C-15),29.4(C-16),37.5(C-17),49.2(C-18),66.1(C-19),31.0(C-20),32.7(C-21),38.4(C-22),27.2(C-23),24.1(C-24),15.7(C-25),16.9(C-26),21.6(C-27),17.0(C-28),33.4(C-29),28.2(C-30),173.9(C-1′),35.0(C-2′),25.3(C-3′),29.5(C-4′),29.6(C-5′),29.7(C-6′),29.8(C-7′),29.8(C-8′),29.8(C-9′),29.8(C-10′),29.8(C-11′),30.7(C-12′),32.1(C-13′),34.3(C-14′),22.8(C-15′),14.3(C-16′)。 3. The natural pentacyclic triterpene palmitate according to claim 1, characterized in that: The pentacyclic triterpene palmitate has α-glucosidase inhibitory activity and glucose consumption promoting activity at the cellular level; the pentacyclic triterpene palmitate has α-glucosidase inhibitory activity, and its IC 50 =13.65 μM, which is lower than the clinically used α-glucosidase inhibitor acarbose (IC 50 =250.14 μM) was 18 times higher; in addition, the compound had significant glucose consumption promoting activity, and 50 μM of pentacyclic triterpene palmitate was even comparable to the activity of 500 μM of metformin.

4. The method for separation, extraction and structural identification of natural pentacyclic triterpene palmitate according to any one of claims 1 to 3, characterized in that: Here are the steps: (1) Preparation method of golden chrysanthemum ethanol extract First, the dried golden chrysanthemum flowers were crushed to obtain golden chrysanthemum powder, and the powder was placed in a round-bottom flask, and 95% ethanol was added at a solid-liquid ratio of 1:

10. The extraction was performed under reflux at 95°C for 2 times, each time for 2 hours, and the 2 extracts were combined and concentrated under reduced pressure to obtain an ethanol extract, with a total extraction rate of 40.27%; (2) Method for refining golden chrysanthemum ethanol extract S1: Petroleum ether fractionation method of extract Ultrasonic dispersion of the alcohol extract in water, with a solid-liquid ratio of g:mL of 1:10, extraction of the dispersed aqueous solution with petroleum ether for 3 times, with a petroleum ether:alcohol extract ratio of mL:g of 300:20, combining the petroleum ether layers and concentrating under reduced pressure; repeating the above operation 50 times to obtain a PE layer extract; S2: Macroporous resin enrichment of extracts Add ethanol EtOH to the PE layer extract and ultrasonicate until dissolved; wet sample loading, separation with AB-8 macroporous resin, elution gradient EtOH / H2O (0%, 20%, 40%, 60%, 80%, 100%, v / v, volume ratio), elution volume of each gradient for every 20g PE layer extract is 2.4L, and 6 components, namely PE0-PE100, are obtained after elution; repeat the above operation 7 times to obtain components PE0, PE20, PE40, PE60, PE80 and PE100; S3: Silica gel column separation method for extracts Component PE100 has low polarity and good separation on TLC, so silica gel column chromatography is used to roughly segment component PE100; component PE100 is separated by silica gel column, and the elution gradient is PE: acetone AC = 500: 1 ~ 30: 1 (v / v, volume ratio), DCM: MeOH = 100: 1 ~ 0: 1 (v / v, volume ratio), and 8 components, namely PE100-1, PE100-2, PE100-3, PE100-4, PE100-5, PE100-6, PE100-7, PE100-8) are obtained; S4: Purification method of target compound in extract Component PE100-2 was separated by a silica gel column with an elution gradient of PE:AC = 400:1 to 200:1 (v / v, volume ratio) to obtain three components, namely PE100-2-1, PE100-2-2, and PE100-2-3; component PE100-2-3 was separated by a silica gel column with an elution gradient of PE:AC = 400:1 to 30:1 (v / v, volume ratio) to obtain six components, namely PE100-2-3-1, PE100-2-3-2, PE100-2-3-3, PE100-2-3-4, PE100-2-3-5, and PE100-2-3-6; component PE100-2-3-5 was separated by an ODS reverse phase column and eluted with MeOH to obtain 87.0 mg of the target compound, with a yield of 0.0147% calculated from the petals of Chrysanthemum morifolium.

5. A golden chrysanthemum extract containing the 3β,19α-dihydroxyolean-12-ene-3-O-palmitate as claimed in claim 1, characterized in that: The content of 3β,19α-dihydroxyolean-12-ene-3-O-palmitate in the extract is 0.001% to 90% (mass ratio), and the steps of the extraction and separation method of the golden chrysanthemum extract are as follows: (1) Preparation method of golden chrysanthemum ethanol extract First, the dried golden chrysanthemum flowers were crushed to obtain golden chrysanthemum powder, and the powder was placed in a round-bottom flask, and 95% ethanol was added at a solid-liquid ratio of 1:

10. The extraction was performed under reflux at 95°C for 2 times, each time for 2 hours, and the 2 extracts were combined and concentrated under reduced pressure to obtain an ethanol extract, with a total extraction rate of 40.27%; (2) Method for refining golden chrysanthemum ethanol extract S1: Petroleum ether fractionation method of extract Ultrasonic dispersion of the alcohol extract in water, with a solid-liquid ratio of g / mL of 1:10, extraction of the dispersed aqueous solution with petroleum ether for 3 times, with a petroleum ether: alcohol extract ratio of mL:g of 300:20, combining the petroleum ether layers and concentrating under reduced pressure; repeating the above operation 50 times to obtain a PE layer extract; S2: Macroporous resin enrichment of extracts Add ethanol EtOH to the PE layer extract and ultrasonicate until dissolved; wet sample loading, separation with AB-8 macroporous resin, elution gradient EtOH / H2O (0%, 20%, 40%, 60%, 80%, 100%, v / v, volume ratio), elution volume of each gradient for every 20g PE layer extract is 2.4L, and 6 components, namely PE0-PE100, are obtained after elution; repeat the above operation 7 times to obtain components PE0, PE20, PE40, PE60, PE80 and PE100; S3: Silica gel column separation method for extracts Component PE100 has low polarity and good separation on TLC, so silica gel column chromatography is used to roughly segment component PE100; component PE100 is separated by silica gel column, and the elution gradient is PE: acetone AC = 500: 1 ~ 30: 1 (v / v, volume ratio), DCM: MeOH = 100: 1 ~ 0: 1 (v / v, volume ratio), and 8 components, namely PE100-1, PE100-2, PE100-3, PE100-4, PE100-5, PE100-6, PE100-7, PE100-8) are obtained; S4: Purification method of target compound in extract The component PE100-2 was separated by a silica gel column with an elution gradient of PE:AC=400:1-200:1 (v / v, volume ratio), and three components, namely PE100-2-1, PE100-2-2, and PE100-2-3, were obtained; the component PE100-2-3 was separated by a silica gel column with an elution gradient of PE:AC=400:1-30:1 (v / v, volume ratio), and six components, namely PE100-2-3- 1. PE100-2-3-2, PE100-2-3-3, PE100-2-3-4, PE100-2-3-5 and PE100-2-3-6; component PE100-2-3-5 was separated by ODS reverse phase column and eluted by MeOH to obtain a golden chrysanthemum extract containing 0.001% to 90% (mass ratio) of 3β,19α-dihydroxyolean-12-ene-3-O-palmitate.

6. Use of the natural pentacyclic triterpene palmitate according to any one of claims 1 to 3 as and / or in the preparation of a marker for a chrysanthemum extract for food or drug addition.

7. Use of the natural pentacyclic triterpene palmitate according to any one of claims 1 to 3 in the preparation of medicines and / or functional foods for treating diabetes.

8. Use of the natural pentacyclic triterpene palmitate according to any one of claims 1 to 3 in the preparation of drugs for treating hyperglycemia-related diseases.

9. Use of the Chrysanthemum chrysantha extract containing natural pentacyclic triterpene palmitate as claimed in any one of claim 5 in the preparation of hypoglycemic foods and / or medicines.